Many promising drugs struggle to reach the cells they are meant to treat. Dense tumour tissue, poor blood supply and the cell membrane itself all act as barriers. Sonoporation is one way to help: using ultrasound and microbubbles to make cell membranes temporarily more permeable, at a precise location, so more of a drug gets in.
Our team has worked on sonoporation for more than a decade, from high-speed microscopy of single bubbles to a first-in-human clinical trial. This article explains the principle, the evidence and the engineering involved.
How sonoporation works
Microbubbles are tiny gas bubbles, a few micrometres across, stabilised by a lipid, protein or polymer shell. Several are already approved as ultrasound contrast agents for diagnostic imaging, such as SonoVue®, Sonazoid™ and Optison™.
In an ultrasound field, microbubbles oscillate: they expand and contract with every pressure cycle. Close to a cell, that motion produces local mechanical forces and micro-streaming that can open transient pores in the cell membrane. These pores reseal, typically within seconds to minutes, but while they are open, molecules that normally enter cells poorly can pass through more easily. The effect is confined to where the ultrasound is focused and where bubbles are present.
The mechanisms are still an active research area, involving both pore formation and enhanced uptake through the cell’s own transport pathways. We reviewed them in Sonoporation: mechanistic insights and ongoing challenges for gene transfer.
From the lab to patients
Sonoporation has moved steadily from cell studies towards the clinic, particularly for pancreatic cancer, where poor drug delivery is a major obstacle.
- In a clinical case study, we combined gemcitabine chemotherapy with microbubbles and a commercial diagnostic ultrasound scanner, using low acoustic intensities.
- This led to a first-in-human clinical trial in patients with inoperable pancreatic cancer, which showed the approach could be delivered with standard clinical equipment and was well tolerated, motivating further studies.
- Preclinical work has explored which clinically approved microbubble performs best for low-intensity sonoporation, and how treatment parameters should be selected.
- Related approaches, such as Acoustic Cluster Therapy, use engineered microbubble–microdroplet clusters and have also reached clinical trials.
The engineering behind it
Sonoporation sits at the meeting point of acoustics, biology and clinical practice. Getting it right means controlling:
- Acoustic parameters: frequency, pressure (mechanical index), pulse length and duty cycle. Too little and nothing happens; too much and you risk tissue damage.
- Exposure geometry: where the beam goes, how it is focused, and how it interacts with tissue and bone.
- Safety and dosimetry: ultrasound output is regulated through indices such as the mechanical and thermal index, and measured outputs do not always match the displayed values, as we showed for clinical diagnostic transducers.
- Microbubble behaviour: size distribution, shell properties and how bubbles respond near boundaries and cells.
- Reproducible experiments: purpose-built exposure chambers and protocols, such as our open-source, high-throughput treatment chamber.
Where it is heading
Research continues into combining sonoporation with chemotherapy, immunotherapy and gene therapy, into new bubble and droplet formulations, and into imaging-guided systems that can deliver and monitor treatment at the same time.
If you are developing an ultrasound-mediated therapy, a drug-delivery formulation, or the devices to deliver them, we can help with experimental design, acoustics, exposure systems and the path to clinical studies. Get in touch.
Further reading: see our full list of publications.
